Can you create a 25‑slide PowerPoint presentation on recent updates in chronic obstructive pulmonary disease (COPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Updates in COPD: 25-Slide PowerPoint Presentation


Slide 1: Title Slide

Recent Updates in Chronic Obstructive Pulmonary Disease (COPD) Evidence-Based Advances in Diagnosis and Management


Slide 2: The Paradigm Shift in COPD Management

COPD management has fundamentally transformed from empirical bronchodilation to precision medicine based on treatable traits 1, 2. The 2024-2026 period marks a historic inflection point with three mechanistically distinct agents receiving FDA approval—the first substantive pharmacological innovation in over two decades 1.

Key transition:

  • From: One-size-fits-all bronchodilator approach
  • To: Biomarker-driven, pathobiology-aligned precision treatment

Slide 3: Updated Risk Stratification Framework

The 2023 Canadian Thoracic Society guideline provides clear exacerbation risk definitions 3:

Low Risk:

  • ≤1 moderate exacerbation in past year
  • No hospital admission/ED visit

High Risk:

  • ≥2 moderate exacerbations OR
  • ≥1 severe exacerbation (hospitalization/ED visit) in past year

This stratification drives all subsequent treatment decisions.


Slide 4: Symptom Assessment Tools

Use validated instruments to quantify symptom burden 3:

  • CAT (COPD Assessment Test): Simple, validated tool
    • Score <10: Low symptom burden
    • Score ≥10: Moderate to high symptoms
  • mMRC (Modified Medical Research Council): Dyspnea grading
    • Score ≥2: Significant breathlessness

These scores directly determine initial therapy selection.


Slide 5: Initial Treatment Algorithm - Low Symptoms, Low Risk

For patients with CAT <10 and FEV₁ ≥80% predicted 3:

Start with single long-acting bronchodilator (LABD):

  • Either LAMA or LABA
  • Choice based on availability and patient response
  • Add short-acting bronchodilator (SABD) as needed

This represents the minimal effective therapy for mild disease.


Slide 6: Initial Treatment - Moderate to High Symptoms

For patients with mMRC ≥2, CAT ≥10, and FEV₁ <80% predicted 3:

LAMA/LABA dual therapy is the recommended initial maintenance treatment.

Critical point: LAMA/LABA is preferred over ICS/LABA due to:

  • Superior lung function improvements
  • Lower pneumonia rates 3, 4

Exception: Use ICS/LABA only if concomitant asthma is present 3.


Slide 7: Triple Therapy Indications

LAMA/LABA/ICS triple combination therapy is recommended for symptomatic patients at high risk of exacerbations 3.

Preferably administered as single-inhaler triple therapy (SITT) rather than multiple inhalers 3.

Triple therapy improves:

  • Lung function
  • Symptoms and health status
  • Reduces exacerbations compared to dual therapy 4

Slide 8: The ICS Controversy - When to Use

ICS use requires careful patient selection due to significant risks 4:

Use ICS when:

  • High exacerbation risk despite LABA/LAMA
  • Concomitant asthma
  • Elevated blood eosinophil counts (see biomarker section)

ICS increases risk of:

  • Pneumonia (especially in severe disease)
  • Oral candidiasis
  • Skin bruising
  • Possible diabetes/cataracts/mycobacterial infection 4

Slide 9: ICS Withdrawal Considerations

Weak recommendation to continue triple therapy rather than stepping down to LAMA/LABA in patients with 3:

  • CAT ≥10 AND/OR
  • FEV₁ <80% predicted

However, ICS withdrawal may be appropriate when:

  • Recurrent pneumonia occurs
  • No exacerbation benefit observed
  • Low eosinophil counts

Evidence on withdrawal remains equivocal 4.


Slide 10: Blood Eosinophils - The Key Biomarker

Blood eosinophil count (BEC) enables precision medicine in COPD 2, 5.

Higher BEC predicts:

  • Greater response to ICS therapy
  • Better response to biologic agents targeting type 2 inflammation
  • Exacerbations may be more steroid-responsive 4

Clinical application: Use BEC to guide ICS initiation and biologic therapy selection 2.


Slide 11: Novel Biologics - Dupilumab

Dupilumab (anti-IL-4/IL-13) represents breakthrough therapy for eosinophilic COPD phenotypes 1, 2, 5.

Demonstrated efficacy:

  • Significant exacerbation reduction in eosinophil-enriched populations
  • Improved lung function
  • First biologic to show substantial benefit in COPD

Target population: Patients with elevated eosinophils and persistent exacerbations despite optimal inhaled therapy.


Slide 12: Other Emerging Biologics

Additional biologic targets showing promise 1, 5:

Anti-IL-5 pathway (Mepolizumab):

  • Targets eosinophilic inflammation
  • Reduces exacerbations in selected patients

Upstream alarmin antagonists:

  • Anti-IL-33
  • Anti-TSLP (thymic stromal lymphopoietin)

These agents shift treatment from widespread inflammation to precise molecular targets.


Slide 13: Ensifentrine - Novel Dual PDE Inhibitor

Ensifentrine represents the first novel inhaled small molecule in decades 1, 2.

Mechanism: Dual phosphodiesterase-3/4 inhibition

Advantages over oral roflumilast:

  • Inhaled delivery reduces systemic side effects
  • Combines bronchodilation with anti-inflammatory effects

This addresses a critical gap in COPD pharmacotherapy.


Slide 14: Oral Adjunctive Therapies - Roflumilast

PDE-4 inhibitor for specific patient populations 4:

Indications:

  • FEV₁ <50% predicted
  • Chronic bronchitis phenotype
  • ≥1 hospitalization for exacerbation in previous year
  • Already on LABA/LAMA/ICS with persistent exacerbations

Mechanism: Reduces moderate and severe exacerbations 4.

Limitation: Gastrointestinal side effects common.


Slide 15: Macrolide Therapy

Long-term azithromycin or erythromycin reduces exacerbations over one year 4.

Specific indication:

  • Former smokers (not current smokers)
  • Persistent exacerbations despite optimal inhaled therapy
  • Chronic bronchitis phenotype 4

Critical caveat: Associated with bacterial resistance development and hearing impairment 4. Weigh benefits against antimicrobial stewardship concerns.


Slide 16: Mucolytic Agents

N-acetylcysteine (NAC) and carbocysteine reduce exacerbation risk in select populations 4.

Target patients:

  • Chronic bronchitis with frequent exacerbations
  • Not recommended for all COPD patients

Evidence level: Moderate (Evidence B) 4.

Antioxidant mucolytics recommended only in selected patients, not as universal therapy.


Slide 17: What NOT to Use

Strong recommendations against certain therapies 3, 4:

Do NOT use:

  • ICS monotherapy in stable COPD with low exacerbation risk 3
  • Long-term oral corticosteroids (no benefit, multiple complications) 4
  • Methylxanthines for exacerbations (side effects outweigh benefits) 4
  • Statins for exacerbation prevention (no benefit in dedicated trials) 4

Slide 18: Smoking Cessation - Still Paramount

Smoking cessation remains the only intervention that modifies long-term lung function decline 4.

Effective strategies:

  • Pharmacotherapy: Varenicline, bupropion, nortriptyline (increase quit rates) 4
  • Nicotine replacement: More effective than placebo 4
  • Counseling: Professional support significantly increases success 4
  • Combination: Pharmacotherapy + behavioral support = highest success 4

E-cigarettes: Efficacy as cessation aid remains controversial 4.


Slide 19: Vaccination Strategies

Vaccinations decrease lower respiratory tract infections 4:

Influenza vaccination:

  • Reduces serious illness, death, and exacerbations 4
  • Decreases ischemic heart disease risk 4
  • Use killed or live inactivated viruses 4

Pneumococcal vaccination:

  • PCV13 and PPSV23 recommended for all patients ≥65 years 4

These are evidence-based, cost-effective interventions.


Slide 20: Pulmonary Rehabilitation

Pulmonary rehabilitation improves symptoms, quality of life, and physical/emotional participation in daily activities 4.

Target patients:

  • High symptom burden (Groups B, C, D)
  • High exacerbation risk
  • Consider individual characteristics and comorbidities 4

Components:

  • Combination of aerobic and strength training most effective 4
  • Tiotropium improves rehabilitation effectiveness 4

Slide 21: Exacerbation Management - Acute Treatment

Key principles for acute exacerbations 4:

Bronchodilators:

  • Short-acting β₂-agonists ± short-acting anticholinergics as initial therapy 4
  • Initiate long-acting bronchodilators before hospital discharge 4

Systemic corticosteroids:

  • Improve FEV₁, oxygenation, recovery time, and hospitalization duration 4

Antibiotics:

  • When indicated (purulent sputum), shorten recovery and reduce relapse 4

Slide 22: Exacerbation Classification and Risk

Exacerbations classified by severity 4:

  • Mild: Treated with short-acting bronchodilators only
  • Moderate: Requires antibiotics and/or oral corticosteroids
  • Severe: Hospitalization or ED visit required

Frequent exacerbators (≥2 per year):

  • Worse health status and morbidity 4
  • Require escalation to triple therapy or adjunctive agents
  • 20% not recovered at 8 weeks 4

Slide 23: Long-Term Oxygen and Ventilation

Oxygen therapy indications 4:

Long-term oxygen improves survival in:

  • Severe resting chronic hypoxemia

Do NOT routinely prescribe for:

  • Stable COPD with resting or exercise-induced moderate desaturation 4

Long-term noninvasive ventilation:

  • May decrease mortality in severe chronic hypercapnia with history of acute respiratory failure hospitalization 4

Slide 24: The Treatable Traits Framework

COPD management shifts from categorical diagnosis to identification of specific, modifiable pathobiological characteristics 1:

Key treatable traits:

  • Eosinophilic inflammation → ICS, biologics
  • Frequent exacerbations → Triple therapy, macrolides, PDE-4 inhibitors
  • Chronic bronchitis → Mucolytics, roflumilast
  • Smoking → Cessation interventions
  • Deconditioning → Pulmonary rehabilitation

This framework enables truly personalized medicine.


Slide 25: Future Directions and Emerging Technologies

COPD therapeutics at the threshold of disease modification 1, 5:

Emerging approaches:

  • Gene editing technologies
  • Senolytic therapy (targeting cellular senescence)
  • Advanced biomarker panels for phenotyping
  • Artificial intelligence-assisted CT analysis for early detection 5
  • Multi-tiered screening systems based on healthcare resource stratification 5

The convergence of biologics, small molecules, and emerging technologies positions COPD management for transformative change 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.